CBD in Vaporised Cannabis Raises THC Blood Levels, Study Finds—but Age Differences Remain Unclear
By Dr. Benjamin Caplan, MD | Board-Certified Family Physician, CMO at CED Clinic | Evidence Watch
A randomised crossover trial found that vaporising cannabis containing both CBD and THC produced significantly higher THC blood levels than vaporising THC alone. This finding challenges assumptions from earlier inhalation studies and has implications for both recreational cannabis users and clinical dosing, though the small sample size and limited blood-draw schedule mean the results should be treated as preliminary.
CBD in Vaporised Cannabis Raises THC Blood Levels, Study Finds, but Age Differences Remain Unclear
A randomised crossover trial in adolescents and adults shows co-inhaled CBD elevated circulating THC and metabolites, challenging assumptions from earlier inhalation studies and raising important questions about cannabinoid interaction pharmacokinetics when cannabis is vaporised rather than taken orally.
#72
Strong Clinical Relevance
Directly addresses a contested pharmacokinetic interaction with immediate implications for cannabis dosing, product formulation, and forensic blood-level interpretation.
Pharmacokinetics
Vaporised Cannabis
Adolescent Health
Crossover RCT
As cannabis products increasingly combine THC and CBD at various ratios, understanding whether CBD modifies how much THC reaches the bloodstream is critical for clinicians, patients, and regulators. Many consumers and practitioners assume that adding CBD to THC blunts intoxication or reduces exposure, but the pharmacokinetic basis for this belief has remained contested. If CBD actually increases systemic THC availability after inhalation, current dosing recommendations and product labeling may need to be reconsidered, and the implications for adolescents, a group with distinct neurobiological vulnerabilities, are especially pressing.
The question of whether co-administered CBD alters THC pharmacokinetics has produced contradictory results across studies, with oral administration data generally suggesting inhibition of THC metabolism and inhalation data mostly finding no interaction. This secondary analysis of the CannTeen Acute study, a double-blind, placebo-controlled crossover trial conducted at Hammersmith Hospital in London, enrolled 48 participants equally divided between adolescents aged 16 to 17 and adults aged 26 to 29, with balanced sex representation. Each participant underwent three sessions receiving vaporised THC alone (8 mg per 75 kg body weight), THC combined with CBD at a 1:3 ratio (8 mg THC plus 24 mg CBD per 75 kg), or placebo. Blood was drawn at four time points spanning from 5 minutes before to 160 minutes after inhalation, and plasma was analyzed for THC, 11-hydroxy-THC (OH-THC), 11-nor-9-carboxy-THC (COOH-THC), CBD, and CBD metabolites.
Among the 35 participants with complete pharmacokinetic datasets, the THC-plus-CBD condition produced significantly higher natural-log-transformed area-under-the-curve (AUC) values for THC, OH-THC, and COOH-THC compared to THC alone. Peak concentration (Cmax) was also significantly higher for THC and COOH-THC in the combination condition, though not for OH-THC. No statistically robust age-related pharmacokinetic differences emerged between adolescents and adults, although the study was almost certainly underpowered for this comparison. The authors acknowledge that the sparse four-timepoint blood-draw schedule limits the precision of their AUC and Cmax estimates, and they note the finding conflicts with three prior inhalation studies while aligning with one other vaporisation study by Arkell and colleagues from 2019. Replication with denser sampling protocols and larger samples is needed before firm clinical conclusions can be drawn.
This study asks exactly the right question, and the crossover design with blinded vaporised cannabis is genuinely difficult to execute, so I give credit to the investigators for the rigor they achieved. But the gap between these results and clinical certainty is still substantial. Four blood draws over 160 minutes is not enough to build a confident pharmacokinetic profile, and the fact that 13 of 48 participants dropped out of the PK analysis introduces real concern about selection effects. The direction of the finding, that CBD may boost rather than buffer THC exposure, is provocative and important, but I would not yet call it established.
In practice, I already counsel patients that the relationship between CBD and THC is more complex than “CBD calms THC down.” When patients use combination vaporised products, I advise them to start with lower THC doses than they would use without CBD present, precisely because we cannot yet rule out the possibility that CBD changes THC absorption dynamics. For adolescents in particular, I urge extreme caution with any inhaled cannabis, and this study reinforces that position even as it falls short of providing the definitive PK data we need.
This study sits at a genuinely contested frontier of cannabinoid pharmacology. The oral CBD-THC interaction literature has broadly pointed toward CBD inhibiting CYP enzymes involved in THC metabolism, thereby increasing THC exposure. The inhalation literature, however, has been more ambiguous, with most studies reporting no significant interaction. This trial’s findings, if replicated, would begin to resolve this discordance by suggesting that the interaction does occur with vaporised delivery but may depend on the specific ratio, dose, or vaporisation characteristics. The inclusion of adolescents is a significant contribution, as nearly all prior PK work has been restricted to adults despite the particular clinical importance of understanding cannabinoid disposition in younger users.
From a pharmacological standpoint, the mechanism most likely involves CBD’s known inhibition of CYP2C9 and CYP3A4, both of which contribute to THC hydroxylation and subsequent carboxylation. If
Have thoughts on this? Share it:
